Brookline Capital Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital has initiated coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and set a price target of $8.
June 07, 2024 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Brookline Capital has initiated coverage on SAB Biotherapeutics with a Buy rating and set a price target of $8, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a price target of $8 by Brookline Capital is likely to boost investor confidence and positively impact the stock price of SAB Biotherapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100